secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000318154-24-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q1 2024 revenue up 22% to $7.4B; GAAP EPS loss of $0.21 on BeiGene mark-to-market loss
--------------------------------------------------------------------------------

- Total revenue $7.4B (+22% YoY); product sales grew 22% driven by 25% volume growth; Horizon contributed $914M.
- GAAP EPS loss of $0.21 vs $5.28 gain YoY, driven by mark-to-market loss on BeiGene equity investment.
- Non-GAAP EPS $3.96 (-1% YoY); non-GAAP operating income $3.1B (+11% from $2.8B).
- Ten products delivered double-digit volume growth including Repatha, TEZSPIRE, EVENITY, BLINCYTO, TAVNEOS.
- Free cash flow $0.5B vs $0.7B; decrease from $800M tax deposit partially offset by working capital timing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815424000018/0000318154-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815424000018/amgn-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000318154-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer